Literature DB >> 18467000

Health state utility scores in advanced non-small cell lung cancer.

Scott Doyle1, Andrew Lloyd, Mel Walker.   

Abstract

BACKGROUND: The aim of the study was to capture societal utility scores for health state descriptions of advanced, metastatic non-small cell lung cancer (NSCLC), as well as determine disutility associated with specific disease symptoms.
METHODS: NSCLC health states were produced based on an adaptation of existing health state descriptions for metastatic lung cancer. The health states were expanded to contrast disease state (responding disease and stable disease) and impact of specific severe symptoms (cough; dyspnoea; pain; or no additional severe symptoms). Interviews with five lung cancer clinicians were carried out to assess the content and face validity of the existing health states as descriptions specific to NSCLC. The interviews also sought to explore the impact of the disease symptoms of interest. The resulting health states were reviewed by two psychometric experts independently. The final health states were piloted in a conventional standard gamble interview which revealed no significant issues in interpretation or comprehension. In the main study, 101 members of the general public assessed their preference for each health state in a chained standard gamble (SG) interview and on a visual analogue scale (VAS) rating scale. All participants also completed the EQ-5D and a socio-demographic form.
RESULTS: The study sample was a relatively good match to the characteristics of the general public in England and Wales. A mixed model analysis revealed that age, gender, and HRQL were not significant predictors of utility, but a treatment response and each of the disease symptoms were. When adjusted to match census data, stable disease with no additional symptoms had a utility value of 0.626. Health state values declined by 0.069 with the addition of pain; 0.050 for dyspnoea; or 0.046 for cough. A treatment response would result in a utility gain of 0.086.
CONCLUSIONS: Members of the general public showed a preference for responding disease over stable disease and a stable health state with no additional symptoms over a stable health state with one of the three common NSCLC symptoms: cough, dyspnoea, and pain. The study highlights the value that society places on the avoidance of severe symptoms that some people with NSCLC can experience.

Entities:  

Mesh:

Year:  2008        PMID: 18467000     DOI: 10.1016/j.lungcan.2008.03.019

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  31 in total

1.  Quality of life and healthcare use in a randomized controlled lung cancer screening study.

Authors:  Peter J Mazzone; Nancy Obuchowski; Alex Z Fu; Michael Phillips; Moulay Meziane
Journal:  Ann Am Thorac Soc       Date:  2013-08

2.  Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.

Authors:  Verin Lertjanyakun; Nathorn Chaiyakunapruk; Susumu Kunisawa; Yuichi Imanaka
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

Review 3.  Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review.

Authors:  Mahdi Gharaibeh; J Lyle Bootman; Ali McBride; Jennifer Martin; Ivo Abraham
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

Review 4.  Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique.

Authors:  Bonny Parkinson; Sallie-Anne Pearson; Rosalie Viney
Journal:  Eur J Health Econ       Date:  2013-02-24

5.  Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada.

Authors:  T E Delea; J Amdahl; A Chit; M M Amonkar
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

6.  Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.

Authors:  J Amdahl; J Diaz; J Park; H R Nakhaipour; T E Delea
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

7.  The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis.

Authors:  Grainne M O'Kane; Jie Su; Brandon C Tse; Vivian Tam; Tiffany Tse; Lin Lu; Michael Borean; Emily Tam; Catherine Labbé; Hiten Naik; Nicole Mittmann; Mark K Doherty; Penelope A Bradbury; Natasha B Leighl; Frances A Shepherd; Nadine M Richard; Kim Edelstein; David Shultz; M Catherine Brown; Wei Xu; Doris Howell; Geoffrey Liu
Journal:  Oncologist       Date:  2019-04-05

8.  Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer.

Authors:  Thomas E Delea; Carol Hawkes; Mayur M Amonkar; Konstantinos Lykopoulos; Stephen R D Johnston
Journal:  Breast Care (Basel)       Date:  2013-12       Impact factor: 2.860

9.  Health utility scores of colorectal cancer based on societal preference in Japan.

Authors:  Takeru Shiroiwa; Takashi Fukuda; Kiichiro Tsutani
Journal:  Qual Life Res       Date:  2009-07-21       Impact factor: 4.147

10.  Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.

Authors:  Vakaramoko Diaby; Georges Adunlin; Askal A Ali; Simon B Zeichner; Gilberto de Lima Lopes; Christine G Kohn; Alberto J Montero
Journal:  Breast Cancer Res Treat       Date:  2016-09-21       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.